ertumaxomab

{{Short description|Monoclonal antibody}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 457120720

| type = mab

| mab_type = 3funct

| source = axo

| target = HER2/neu, CD3

| tradename = Rexomun

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 509077-99-0

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = L5L45YGP1O

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.

It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.{{cite web | title = Capital Market Day Fresenius Biotech: Fresenius Concentrates Biotechnology Activities on Antibody and Innovative Cell Therapies | date = 15 January 2004 | url = http://www.fresenius.se/internet/fag/com/faginpub.nsf/Content/P-Info2004_01_15 | archive-url = https://web.archive.org/web/20111001191549/http://www.fresenius.se/internet/fag/com/faginpub.nsf/Content/P-Info2004_01_15 | archive-date = 1 October 2011 | work = Fresenius }}{{cite journal | vauthors = Kiewe P, Thiel E | title = Ertumaxomab: a trifunctional antibody for breast cancer treatment | journal = Expert Opinion on Investigational Drugs | volume = 17 | issue = 10 | pages = 1553–1558 | date = October 2008 | pmid = 18808314 | doi = 10.1517/13543784.17.10.1553 }}

Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.{{ClinicalTrialsGov|NCT00522457|Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy }} (So they could concentrate on their other product catumaxomab (trade name Removab).{{Cite web | title = 2009 Consolidated Financial Statements and Management Report of Fresenius SE | url = https://www.fresenius.com/media/gb_englisch_IFRS_2009.pdf | access-date = 2016-03-20 | archive-date = 2016-03-31 | archive-url = https://web.archive.org/web/20160331111654/https://www.fresenius.com/media/gb_englisch_IFRS_2009.pdf | url-status = dead }}{{rp|35}})